Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2014

Stock-based Compensation

Schedule of stock-based compensation expense related to all of the entity's share-based payments

Total stock-based compensation expense related to all of our share-based payments that we recognized in the quarters ended March 31, 2014 and 2013 was as follows (in thousands):

		Three Months Ended
		March 31,
		2014			2013
Research and development		$	1,314		$	1,023
General and administrative		1,050			770
Total stock-based compensation expense		$	2,364		$	1,793

Summary of weighted-average assumptions relating to options granted pursuant to equity incentive plans

		Equity Incentive Plans
		Three Months Ended
		March 31,
		2014		2013
Risk-free interest rate		2.2	%	0.8	%
Expected term (in years)		6.5		5.5
Dividend yield		0.0	%	0.0	%
Expected volatility		75.2	%	73.4	%

Summary of weighted-average assumptions used to calculate fair value of purchase rights granted under Employee Stock Purchase Plan

		Employee Stock Purchase Plan
		Three Months Ended
		March 31,
		2014		2013
Risk-free interest rate		0.3	%	0.2	%
Expected term (in years)		1.7		1.4
Dividend yield		0.0	%	0.0	%
Expected volatility		66.0	%	58.0	%